Producer and category screening
Review producer background, export readiness and basic file availability.
Operating platform
Aura Med keeps the first conversation focused on category, files, route and counterpart qualification.

Review producer background, export readiness and basic file availability.
Organise the core files that a buyer, pharmacy route or quality team expects first.
Map intended use, counterpart qualification and market constraints before escalation.
Move introductions forward only when role, route and files are clear enough.
What buyers expect to see
Regulated medical cannabis and adjacent healthcare categories often need the same first-pass discipline: route, files and role clarity before commercial claims.
Producer background, facility references, export readiness and document availability.
Core analytical files, specifications, stability notes and missing evidence.
Whether current production and cultivation references match buyer expectations.
Route assumptions, target country, permitted professional use and license position.
White-label, bulk, finished format and market-specific labelling considerations.
GDP, warehousing, batch release and distribution questions routed to qualified partners where required.
Decision boundary
Role, target country, intended use, category sensitivity, file state and counterpart qualification.
Formal legal advice, licensing decisions, product registration, medical claims review or national regulatory determinations.
If country, qualification, documents or lawful intended use are unclear, Aura Med returns a blocker list before partner exposure.
B2B decision psychology
Teams hesitate when the first introduction could create legal review, procurement rework or credibility loss.
Instead of "send everything", Aura Med keeps the first file request tied to one decision: proceed, pause or collect-files.
Every first-pass outcome names the next likely owner: commercial, legal, quality, procurement or supplier-side documentation.